Guilin Sanjin Pharmaceutical Co., Ltd. engages in the research, production, manufacturing, and sale of traditional Chinese medicines in China and internationall...
Guilin Sanjin released its performance for the first three quarters, with a net profit attributable to the parent company of 385 million yuan, a year-on-year increase of 0.35%
Guilin Sanjin plans to distribute 118 million yuan in cash in the first three quarters of 2025
Guilin Sanjin provides an additional guarantee of 20 million yuan for its subsidiary Baochuan Biotechnology
A-share pharmaceutical stocks continue to adjust, CheezhengTTM approaches the limit down, and multiple stocks such as Xintian Pharmaceutical, Hanyu Pharmaceutical, Guilin Sanjin, Foci Pharmaceutical, YIBAI PHARMACEUTICAL, Zhendong Pharmacy, and Cosunter have fallen over 5%
The generic drug consistency evaluation sector has declined in the short term, with Guilin Sanjin falling over 6%
Global Dividend Stocks To Consider In June 2025